Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The CV outcome trials (CVOT) (Figure 1) of all the GLP-1 RAs (liraglutide, semaglutide, dulaglutide, albiglutide, extended-release exenatide, and lixisenatide) (Table 1)
BMJ 367:l6217
We assessed heterogeneity between the included studies using the I statistic, where I 2 values of 25%, 50%, and 75% indicated low, medium, and high heterogeneity, respectively
Hearn EB, Sherman JJ
This is because the negative secondary effects were much more immediate, I believe
Both eventually reach similar endpoints
US$ 21.89
US$ 21.98
US$ 20.90
US$ 28.31
US$ 21.14
